Diarrhea and colitis related to immune checkpoint inhibitor and BRAF/MEK inhibitor therapy

ABSTRACT:

Background

Immune checkpoint inhibitor (ICI) therapy can be complicated by gastrointestinal adverse events (AEs). Similarly, gastrointestinal AEs have been reported with the use of serine/threonine-protein kinase B-Raf (BRAF) and mitogen-activated protein kinase kinase (MEK) inhibitor therapy. We investigated the characteristics and management of gastrointestinal AEs related to sequential ICI and BRAF/MEK inhibitor therapy.

Methods

We identified 255 adult cancer patients who received both BRAF/MEK inhibitor therapy and ICI therapy between 2014 and 2021. Thirty-two eligible patients had gastrointestinal AEs after receiving both therapies and were categorized based on the order of their administration. Their clinical characteristics, evaluation, treatment and outcomes were

SUBMITTER: Kuang A 

PROVIDER: S-EPMC9756030 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature